Erez Aminov

Erez Aminov is a distinguished executive and entrepreneur with deep-rooted expertise in the biotech and technology sectors. Since April 2023, he has led MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) as Director and Chief Executive Officer, guiding the company through its preclinical-stage endeavors. At MIRA Pharmaceuticals, Mr. Aminov is focused on developing the next generation of oral ketamine and pharmaceutical marijuana analogs to treat neurologic and neuropsychiatric disorders. A key focus of this effort is Ketamir-2, a groundbreaking ketamine analog currently under investigation for its potential to deliver ultra-rapid, orally administered antidepressant effects for patients unresponsive to conventional treatments, offering new hope to those battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI). In recognition of his leadership, Mr. Aminov was appointed Chairman of the company in March 2024.

In August 2024, Mr. Aminov further expanded his leadership portfolio by becoming the Chairman and Chief Executive Officer of Telomir Pharmaceuticals. At Telomir, he continues to leverage his extensive industry experience to guide the company’s strategic direction. Telomir-1, one of the company’s key projects, is under investigation as a potential therapeutic intervention against age-related inflammatory conditions. The drug is being developed to protect stem cells by elongating and stimulating telomeres, thus sustaining their self-renewal.

Mr. Aminov’s journey into the biotech sector began in September 2021 when he founded Locate Venture Corp., a strategy and investment consulting firm dedicated to advancing early-stage biotech startups. With over two decades of industry experience, he has adeptly navigated the complex challenges of the biotech sector, forged strategic alliances, and successfully guided startups toward sustainable growth. Mr. Aminov holds a B.A. in Accounting from Touro University in New York. His financial acumen and investment expertise, particularly in early-stage life sciences companies, make him an exceptional leader and valuable asset in the biotech industry.